SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for IGC Pharma, Inc. (IGC) (CIK 0001326205) (IGC) — Jul 17, 2014

IGC Pharma, Inc. (IGC) (CIK 0001326205)
Date: July 17, 2014 · CIK: 0001326205 · Accession: 0000000000-14-036204

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
July 17, 2014
Author
/s/Tia L. Jenkins
Form
UPLOAD
Company
IGC Pharma, Inc. (IGC) (CIK 0001326205)

Letter

July 1 7, 2014 Via E -mail Ram Mukunda Chief Executive Officer India Globalization Capital, Inc. 4336 Montgomery Ave. Bethesda, M D 20814

Re: India Globalization Capital , Inc. Form 10-K for the Fiscal Year Ended March 31 , 2013 Filed July 16 , 201 3 File No. 001 -32830

Dear Mr. Mukunda :

We have comple ted our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/Tia L. Jenkins

Show Raw Text
July 1 7, 2014

Via E -mail
Ram Mukunda
Chief Executive  Officer
India  Globalization Capital, Inc.
4336 Montgomery Ave.
Bethesda, M D 20814

Re: India  Globalization Capital , Inc.
 Form 10-K for the Fiscal Year Ended March 31 , 2013
Filed July 16 , 201 3
File No. 001 -32830

Dear Mr. Mukunda :

We have comple ted our review of your filing .  We remind you that our comments or
changes to disclosure in response to our comments do not foreclose the Commission from taking
any action with respect  to the company or the filing  and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United  States.  We urge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing  to be certain that the filing includes  the
information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

 /s/Tia L. Jenkins

Tia L. Jenkins
Senior Assistant Chief Accountant
Office of Beverages, Apparel , and
Mining